PT-141

PT-141, known generically as bremelanotide, is a synthetic cyclic peptide built as an analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural signaling molecule in the melanocortin system. It traces back to research on Melanotan II, a tanning peptide, where investigators noticed that participants were unexpectedly reporting increased sexual arousal. That observation split into its own line of research, and PT-141 was engineered from the same parent chemistry to be more selective, favoring the receptor tied to sexual function rather than the ones driving pigmentation or appetite. The compound was developed commercially by Palatin Technologies, and in 2019 the FDA approved it under the brand name Vyleesi for a specific condition in premenopausal women. It is therefore one of the few peptides in the wellness space that has crossed fully into the regulated pharmaceutical world.

The FDA-approved use is hypoactive sexual desire disorder, meaning clinically low sexual desire that causes personal distress, in premenopausal women. Beyond that label, clinics use PT-141 off-label for men, particularly those with erectile difficulty who did not respond well to Viagra or Cialis, and for arousal complaints in women outside the approved group. Because it acts on desire rather than blood flow, people often turn to it when the core issue is motivation or interest rather than physical capacity. A commonly discussed pairing is combining it with a PDE5 inhibitor such as sildenafil, on the logic that one generates the upstream signal in the brain while the other supports the downstream vascular response. Some early interest also exists in its dopaminergic effects on mood and motivation, though that use is speculative.

PT-141 works in the brain, not on the plumbing, which sets it apart from Viagra and Cialis. It crosses into the central nervous system and activates melanocortin MC4 receptors, concentrated in the medial preoptic area of the hypothalamus, a region that governs sexual desire and arousal in both men and women. Activating those receptors is thought to increase dopamine release, which amplifies the neural circuits that generate desire, so the effect is described as raising the want rather than just enabling the response. A distinctive quirk is that the effects outlast the molecule itself: its half-life is only about 2.7 hours, yet reported effects can persist from roughly 6 to 24 hours, likely because the peptide sets off a neurochemical cascade that continues after the drug has cleared. Its relative selectivity for MC4, compared with the broader receptor activity of Melanotan II, is what is credited with giving it the sexual effect without the tanning and appetite changes.

PT-141 is a systemic agent, meaning it acts throughout the body via the brain rather than at a local site. The clinically studied and approved route is subcutaneous injection, with reported protocols describing a 1.75 mg dose taken on an as-needed basis at least 45 minutes before anticipated activity, rather than on a daily schedule. Guidance from the trials describes no more than one dose in 24 hours and a monthly ceiling, a cap attributed largely to a hyperpigmentation risk that rose sharply with frequent consecutive dosing but stayed low at the intermittent frequency. Earlier research also explored an intranasal form, including one small study that paired low-dose intranasal PT-141 with low-dose sildenafil, but the injectable is what standard use has settled on. None of this is a protocol recommendation, and cadence in off-label and compounded settings varies.

The strongest data sits with women, where two phase 3 randomized controlled trials, the Reconnect trials published by Kingsberg and colleagues in 2019, studied roughly 1,247 premenopausal women with hypoactive sexual desire disorder, and a longer extension followed hundreds more for about a year. The effects on desire and distress were statistically significant and durable, but the honest picture is that they were modest: the placebo response was high at around 35 percent, and discontinuation in the treatment arms was substantial, driven largely by nausea, with the trials funded by the manufacturer. Evidence in men is earlier and thinner, resting on a 2004 study by Rosen and colleagues showing dose-dependent erectile response in Viagra non-responders and a small 2024 observational report by Goldstein and Goldstein in 21 men with no control group. So the mechanism is well characterized and the female indication is genuinely trial-backed, while male use is reasonable extrapolation rather than proven at the same level. The most common side effects reported are nausea, transient rises in blood pressure, flushing, and headache.

Bremelanotide is FDA-approved as the prescription drug Vyleesi, cleared in 2019 for hypoactive sexual desire disorder in premenopausal women, which makes PT-141 unusual among peptides in having a formal regulatory pathway. Use in men and in postmenopausal women falls outside that label and is considered off-label. Alongside the branded product, PT-141 is widely sold in gray-market and compounded channels as a research peptide, where purity, dosing, and oversight are not guaranteed. It is not a scheduled controlled substance, and it is not a prominent athletic doping agent, so it is generally discussed in the context of sexual health rather than sports anti-doping rules. As with all peptides, the regulatory and enforcement landscape shifts quickly, so current status should be verified rather than assumed.